Can not agree with your statement that mpl hasn't missed a target, the main endpoint for the phase 2b canine trial was to reach 18 out of 46 dogs showing the required improvement, it failed to reach this.
That is a false statemnentt. Nobody ever said this was going to be a cure for the ultra-aggressive B cell lymphoma in dogs but it did, on average, measurably extend their lives and the point was that it was an alternative to chemo.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1137
-
- There are more pages in this discussion • 288 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.8¢ | $151.1K | 877.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 54714 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 371375 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |